Princeton, N.J., Aug. 27 /PRNewswire-FirstCall/ -- Pharmacopeia , an innovator in the discovery and development of novel small molecule therapeutics, announced today that the company will assist the World Health Organization’s Special Program for Research and Training in Tropical Diseases (WHO/TDR) in its efforts to develop novel antimalarial agents. Pharmacopeia will receive funding to conduct medicinal chemistry research on compounds identified through WHO/TDR’s drug screening program involving a network of centers in developed and developing countries. The goal of this project is to identify new lead series with the potential to become novel malaria drug candidates. Malaria kills more than one million people a year, with most of those being children in the developing world.
For more information about Pharmacopeia, please visit http://www.pharmacopeia.com. Contact: Amy Sharpless 609-452-3643 ir_pr@pcop.com
Pharmacopeia
CONTACT: Amy Sharpless of Pharmacopeia, +1-609-452-3643, ir_pr@pcop.com
Web site: http://www.pharmacopeia.com/
